EMA Authorised: Dupixent (dupilumab) — Sanofi Winthrop Industrie

View source ↗

Summary

The EMA has authorised Dupixent (dupilumab) for multiple indications including atopic dermatitis, prurigo, esophageal diseases, asthma, and sinusitis, with Sano…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Atopic Dermatitis
• Esophageal Diseases
• Prurigo
• Rhinosinusitis with Nasal Polyps

Drugs mentioned

• DUPIXENT (DUPILUMAB)

Snippet

Status: Authorised. Therapeutic area: Dermatitis, Atopic;Prurigo;Esophageal Diseases;Asthma;Sinusitis. MAH: Sanofi Winthrop Industrie. Decision date: 09/07/2026